Therapeutic applications of carbon monoxide-releasing molecules.

Abstract

Carbon monoxide (CO), which is formed in mammalian cells through the oxidation of haem by the enzyme haem oxygenase, actively participates in the regulation of key intracellular functions. Emerging evidence reveals that an increased generation of haem oxygenase-derived CO plays a critical role in the resolution of inflammatory processes and alleviation of cardiovascular disorders. The authors have identified a novel class of substances, CO-releasing molecules (CO-RMs), which are capable of exerting a variety of pharmacological activities via the liberation of controlled amounts of CO in biological systems. A wide range of CO carriers containing manganese (CORM-1), ruthenium (CORM-2 and -3), boron (CORM-A1) and iron (CORM-F3) are currently being investigated to tailor therapeutic approaches for the prevention of vascular dysfunction, inflammation, tissue ischaemia and organ rejection.

• Authors: Roberto Motterlini, Brian E Mann, Roberta Foresti
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 14 Issue 11 Pg. 1305-18 (Nov 2005) ISSN: 1744-7658 [Electronic] England
• PMID: 16255672 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anti-Inflammatory Agents
• Boranes
• Carbonates
• Organometallic Compounds
• sodium boranocarbonate
• tricarbonylchloro(glycinato)ruthenium(II)
• tricarbonyldichlororuthenium (II) dimer
• Carbon Monoxide
• Heme Oxygenase-1

Topics

• Animals
• Anti-Inflammatory Agents (pharmacology)
• Blood Pressure (drug effects)
• Boranes (pharmacology, therapeutic use)
• Carbon Monoxide (metabolism)
• Carbonates (pharmacology, therapeutic use)
• Heme Oxygenase-1 (physiology)
• Humans
• Kidney Diseases (drug therapy)
• Myocardial Reperfusion Injury (prevention & control)
• Organometallic Compounds (pharmacology, therapeutic use)